Celyad Oncology S.A.
CYAD.BR · BRU
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €14 | €172 | €14 | €58 |
| % Growth | -91.9% | 1,128.6% | -75.9% | – |
| Cost of Goods Sold | €212 | €224 | €9 | €25 |
| Gross Profit | -€198 | -€52 | €5 | €33 |
| % Margin | -1,414.3% | -30.2% | 35.7% | 56.9% |
| R&D Expenses | €2,100 | €1,776 | €1,537 | €2,529 |
| G&A Expenses | €1,700 | €1,351 | €1,737 | €2,218 |
| SG&A Expenses | €1,700 | €1,461 | €1,737 | €2,320 |
| Sales & Mktg Exp. | €0 | €78 | €0 | €83 |
| Other Operating Expenses | -€100 | -€299 | -€186 | -€104 |
| Operating Expenses | €3,700 | €2,938 | €3,088 | €4,745 |
| Operating Income | -€3,700 | -€2,990 | -€3,083 | -€4,712 |
| % Margin | -26,428.6% | -1,738.4% | -22,021.4% | -8,124.1% |
| Other Income/Exp. Net | €76 | €109 | €4 | -€59 |
| Pre-Tax Income | -€3,700 | -€2,881 | -€3,079 | -€4,771 |
| Tax Expense | €0 | -€102 | €0 | -€85 |
| Net Income | -€3,700 | -€2,779 | -€3,044 | -€4,708 |
| % Margin | -26,428.6% | -1,615.7% | -21,742.9% | -8,117.2% |
| EPS | -0.089 | -0.067 | -0.12 | -0.16 |
| % Growth | -33.2% | 44.1% | 25% | – |
| EPS Diluted | -0.089 | -0.067 | -0.12 | -0.16 |
| Weighted Avg Shares Out | 41,400 | 41,429 | 25,722 | 28,850 |
| Weighted Avg Shares Out Dil | 41,400 | 41,429 | 25,722 | 28,850 |
| Supplemental Information | – | – | – | – |
| Interest Income | €22 | €53 | €100 | €4 |
| Interest Expense | €42 | €58 | €61 | €63 |
| Depreciation & Amortization | €92 | €221 | €229 | €236 |
| EBITDA | -€3,609 | -€2,602 | -€2,789 | -€4,468 |
| % Margin | -25,775% | -1,512.8% | -19,921.4% | -7,703.4% |